Pancreatic neuroendocrine tumors (pNET) are a group of cancers that can occur in the hormone-producing cells of the pancreas. Pancreatic neuroendocrine tumors, also known as islet cell cancers, are very rare.
Pancreatic neuroendocrine tumors begin in small hormone-producing cells (islet cells) normally found in your pancreas.
Some pancreatic neuroendocrine tumor cells continue to secrete hormones (known as functional tumors), creating too much of the given hormone in your body. Examples of these types include gastrinoma and glucagonoma.
Many times these tumors do not secrete an excess amount of these hormones (known as nonfunctional tumors).
Pancreatic neuroendocrine tumors at Mayo Clinic
Pancreatic neuroendocrine tumors sometimes don't cause symptoms. When they do, signs and symptoms can include:
- Stomach ulcers
- Muscle cramps
- Weight loss
- Skin rash
- Pain in your abdomen or back
- Yellowing of your skin or eyes
- Low blood sugar
It's not clear what causes most pancreatic neuroendocrine tumors.
Pancreatic neuroendocrine tumors occur when hormone-producing cells in the pancreas (islet cells) develop changes (mutations) in their DNA — the material that provides instructions for every chemical process in your body. DNA mutations cause changes in these instructions. One result is that cells may begin to grow out of control and eventually form a tumor — a mass of cancerous cells. Sometimes the cancer cells break away and spread to other organs, such as the liver.
Some inherited syndromes increase the risk of this type of cancer, including:
- Multiple endocrine neoplasia, type 1 (MEN 1) syndrome
- Von Hippel-Lindau disease
- Von Recklinghausen's disease (neurofibromatosis 1)
- Tuberous sclerosis
Factors that are associated with an increased risk of pancreatic neuroendocrine tumors include:
- Being male. Men are much more likely than women to develop these tumors.
- A family history of pancreatic neuroendocrine tumors. If a family member was diagnosed with pancreatic neuroendocrine tumor, your risk is increased. You may have multiple endocrine neoplasia, type 1 (MEN 1) syndrome, which increases the risk of this type of tumor.
Pancreatic neuroendocrine tumors care at Mayo Clinic
Dec. 07, 2019
- Niederhuber JE, et al., eds. Cancer of the endocrine system. In: Abeloff's Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed April 24, 2019.
- Neuroendocrine and adrenal tumors. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed Dec. 13, 2018.
- Pancreatic neuroendocrine tumors (islet cell tumors) treatment (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq. Accessed April 24, 2019.
- Goldman L, et al., eds. Pancreatic neuroendocrine tumors. In: Goldman-Cecil Medicine. 25th ed. Saunders Elsevier; 2016. https://www.clinicalkey.com. Accessed Dec. 13, 2018.
- Fact sheet: What is peptide receptor radionuclide therapy (PRRT)? Society of Nuclear Medicine and Molecular Imaging. http://www.snmmi.org/AboutSNMMI/Content.aspx?ItemNumber=29883. Accessed April 9, 2019.
- NPF pancreatic cancer centers. National Pancreas Foundation. https://pancreasfoundation.org/npf-centers-info/pancreatic-cancer-centers/. Accessed June 28, 2019.
- Warner KJ. Allscripts EPSi. Mayo Clinic. Sept. 23, 2019.
- About NCCN. National Comprehensive Cancer Network. https://www.nccn.org/about/default.aspx. Accessed Sept. 24, 2019.
- Panda A, et al. Molecular radionuclide imaging of pancreatic neoplasms. The Lancet Gastroenterology & Hepatology. 2019; doi:10.1016/S2468-1253(19)30081-0.
- Kendi AT, et al. Therapy with 177Lu-DOTATE: Clinical implication and impact on care of patients with neuroendocrine tumors. American Journal of Roentgenology. 2019; doi:10.2214/AJR.19.21123.
- Strosberg J, et al. Phase 3 trial of 177Lu-Dotate for midgut neuroendocrine tumors. The New England Journal of Medicine. 2017; doi:10.1056/NEJMoa1607427.
Pancreatic neuroendocrine tumors